Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR3”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Not applicableLooking for participantsNCT06410976
What this trial is testing

Prospective Clinical Assessment Study in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 150
Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Early research (Phase 1)Looking for participantsNCT05614739
What this trial is testing

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Who this might be right for
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company 535
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Testing effectiveness (Phase 2)Ended earlyNCT02401542
What this trial is testing

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Cell CarcinomaUrinary Bladder DiseaseUrological Diseases
Rainier Therapeutics 71
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07393373
What this trial is testing

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 135
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05145010
What this trial is testing

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 300
Testing effectiveness (Phase 2)Ended earlyNCT00872300
What this trial is testing

PHA-739358 for the Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nerviano Medical Sciences 7
Testing effectiveness (Phase 2)Ended earlyNCT02952573
What this trial is testing

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Who this might be right for
Multiple MyelomaRelapsed/Refractory
University Health Network, Toronto 20
Testing effectiveness (Phase 2)Study completedNCT01058434
What this trial is testing

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 43
Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT04917809
What this trial is testing

Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Who this might be right for
Bladder CancerRecurrent Bladder CancerFGFR3 Gene Mutation
Memorial Sloan Kettering Cancer Center 20
Not applicableUnknownNCT00126958
What this trial is testing

Cost-Effectiveness in Bladder Cancer

Who this might be right for
Bladder Cancer
Erasmus Medical Center 500
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Testing effectiveness (Phase 2)Ended earlyNCT04003610
What this trial is testing

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Incyte Corporation 7
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Testing effectiveness (Phase 2)Ended earlyNCT05363605
What this trial is testing

[225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorHead and Neck Squamous Cell CarcinomaBladder Carcinoma+11 more
Fusion Pharmaceuticals Inc. 6
Testing effectiveness (Phase 2)Looking for participantsNCT07169279
What this trial is testing

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 77
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Load More Results